[go: up one dir, main page]

PE20201284A1 - Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc) - Google Patents

Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc)

Info

Publication number
PE20201284A1
PE20201284A1 PE2020000409A PE2020000409A PE20201284A1 PE 20201284 A1 PE20201284 A1 PE 20201284A1 PE 2020000409 A PE2020000409 A PE 2020000409A PE 2020000409 A PE2020000409 A PE 2020000409A PE 20201284 A1 PE20201284 A1 PE 20201284A1
Authority
PE
Peru
Prior art keywords
present
relates
amicrocitic
nsclc
immunotherapy against
Prior art date
Application number
PE2020000409A
Other languages
English (en)
Inventor
Toni Weinschenk
Steffen Walter
Jens Fritsche
Colette Song
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52460698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20201284(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1313987.8A external-priority patent/GB201313987D0/en
Priority claimed from GBGB1403297.3A external-priority patent/GB201403297D0/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of PE20201284A1 publication Critical patent/PE20201284A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24065—Macrophage elastase (3.4.24.65), i.e. metalloelastase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion se refiere a peptidos, acidos nucleicos y celulas para la utilizacion en metodos inmunoterapeuticos. En concreto, la presente invencion se refiere a la inmunoterapia contra el cancer. La presente invencion se refiere, ademas, a epitopos peptidicos de linfocitos T citotoxicos (CTL) asociados a tumor, solos o en combinacion con otros peptidos asociados a tumor que sirven como principios activos farmaceuticos de composiciones vacunales que estimulan respuestas inmunitarias antitumorales. La presente invencion se refiere a mas de 70 nuevas secuencias peptidicas y sus variantes derivadas de moleculas HLA de clase I y clase II de celulas tumorales humanas que pueden ser utilizadas en composiciones vacunales para desencadenar respuestas inmunitarias antitumorales
PE2020000409A 2013-08-05 2014-08-04 Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc) PE20201284A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361862213P 2013-08-05 2013-08-05
GBGB1313987.8A GB201313987D0 (en) 2013-08-05 2013-08-05 Novel immunotherapy against several tumors, such as lung cancer including NSCLC
GBGB1403297.3A GB201403297D0 (en) 2014-02-25 2014-02-25 Novel immunotherapy against several tumors, such as lung cancer, including NSCLC
PCT/EP2014/066755 WO2015018805A1 (en) 2013-08-05 2014-08-04 Novel immunotherapy against several tumors, such as lung cancer, including nsclc

Publications (1)

Publication Number Publication Date
PE20201284A1 true PE20201284A1 (es) 2020-11-24

Family

ID=52460698

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2015002616A PE20160717A1 (es) 2013-08-05 2014-08-04 Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc)
PE2020000409A PE20201284A1 (es) 2013-08-05 2014-08-04 Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc)
PE2018001559A PE20181538A1 (es) 2013-08-05 2014-08-04 Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2015002616A PE20160717A1 (es) 2013-08-05 2014-08-04 Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc)

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2018001559A PE20181538A1 (es) 2013-08-05 2014-08-04 Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc)

Country Status (28)

Country Link
US (3) US20160168200A1 (es)
EP (10) EP3456339B1 (es)
JP (1) JP2016527293A (es)
KR (9) KR102211542B1 (es)
CN (1) CN105377290B (es)
AU (10) AU2014304544B2 (es)
BR (1) BR112016000810A2 (es)
CA (4) CA3073256A1 (es)
CL (1) CL2016000227A1 (es)
CR (4) CR20200139A (es)
DK (2) DK3456339T3 (es)
EA (1) EA035362B1 (es)
ES (1) ES2764406T3 (es)
HU (1) HUE047079T2 (es)
IL (1) IL243788B (es)
LT (1) LT3030255T (es)
MX (1) MX389568B (es)
NZ (2) NZ714163A (es)
PE (3) PE20160717A1 (es)
PH (1) PH12015502638A1 (es)
PL (1) PL3030255T3 (es)
PT (1) PT3030255T (es)
RS (1) RS59861B1 (es)
SG (4) SG10202002612PA (es)
SI (1) SI3030255T1 (es)
TW (10) TWI819228B (es)
UA (1) UA122661C2 (es)
WO (1) WO2015018805A1 (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
PT3456339T (pt) 2013-08-05 2021-12-09 Immatics Biotechnologies Gmbh Nova imunoterapia contra vários tumores, tais como cancro do pulmão, incluindo cpnpc
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
MY199500A (en) 2015-03-17 2023-11-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
EP4397676A3 (en) 2015-03-27 2024-10-09 Immatics Biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against various tumors
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
TWI772927B (zh) * 2015-03-31 2022-08-01 德商英麥提克生物技術股份有限公司 用於腎細胞癌(rcc)免疫治療的新型肽和肽組合物和支架
GB201505585D0 (en) * 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
PH12021550910A1 (en) * 2015-05-06 2022-03-07 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
PE20180670A1 (es) * 2015-05-20 2018-04-19 Broad Inst Inc Neoantigenos compartidos
MX2017016213A (es) * 2015-06-19 2018-03-07 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia y metodos para crear soportes para el uso contra el cancer de pancreas y otros tipos de cancer.
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MA42294B1 (fr) 2015-07-01 2020-11-30 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
CR20170579A (es) 2015-07-06 2018-05-25 Immatics Biotechnologies Gmbh Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres.
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
TWI796642B (zh) 2015-08-28 2023-03-21 德商英麥提克生物技術股份有限公司 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
US20170136108A1 (en) 2015-08-28 2017-05-18 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201517538D0 (en) * 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
PH12022551111A1 (en) * 2015-10-05 2023-08-23 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
KR20170049024A (ko) * 2015-10-28 2017-05-10 숙명여자대학교산학협력단 ANKs1a 단백질 발현 또는 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 조성물 및 이의 스크리닝 방법
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
HK1255541A1 (zh) 2015-12-11 2019-08-23 Immatics Biotechnologies Gmbh 用於多种癌症免疫治疗的新型肽和肽组合物
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
US10383896B2 (en) 2015-12-11 2019-08-20 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various cancers
BR112018012374A2 (pt) 2015-12-16 2018-12-04 Gritstone Oncology, Inc. identificação, fabricação e uso de neoantígeno
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
HRP20210698T1 (hr) 2015-12-22 2021-09-17 Immatics Biotechnologies Gmbh Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
AU2017247607B2 (en) * 2016-04-06 2021-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against AML and other cancers
EP3445383A1 (en) * 2016-04-21 2019-02-27 Immatics Biotechnologies GmbH Immunotherapy against melanoma and other cancers
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
US10868749B2 (en) * 2016-07-26 2020-12-15 Motorola Mobility Llc Method and apparatus for discovering neighborhood awareness networking devices based on presence
MY195101A (en) * 2016-08-17 2023-01-10 Immatics Biotechnologies Gmbh Novel T Cell Receptors and Immune Therapy Using the Same
TW202304970A (zh) * 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
US11332530B2 (en) 2016-09-23 2022-05-17 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
CN110139875B (zh) * 2016-09-30 2023-03-03 武汉华大吉诺因生物科技有限公司 Col14a1衍生的肿瘤抗原多肽及其应用
JP2020507557A (ja) * 2016-12-01 2020-03-12 ナントミクス，エルエルシー 腫瘍抗原性の処理および提示
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
NZ754222A (en) 2016-12-08 2022-02-25 Immatics Biotechnologies Gmbh T cell receptors with improved pairing
WO2018170313A1 (en) * 2017-03-16 2018-09-20 Advaxis, Inc. Methods and compositions for increasing efficacy of vaccines
CN112521478A (zh) * 2017-04-10 2021-03-19 伊玛提克斯生物技术有限公司 用于白血病和其他癌症免疫治疗的肽和肽组合物
CN117946213A (zh) 2017-04-28 2024-04-30 中山医学大学 治疗癌症的肽
IL315224A (en) 2017-05-08 2024-10-01 Gritstone Bio Inc Neoantigen alphavirus vectors
US10800823B2 (en) 2017-07-07 2020-10-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
CR20210169A (es) 2017-07-07 2021-06-10 Immatics Biotechnologies Gmbh NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO DE LA INMUNOTERAPIA CONTRA EL CÁNCER DE PULMÓN, INCLUYENDO EL NSCLC, EL SCLC Y OTROS CÁNCERES (Divisional 2020-0059)
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
GB201717578D0 (en) * 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor
KR102905054B1 (ko) 2017-11-22 2025-12-29 시애틀 프로젝트 코포레이션 신생항원에 대한 접합 에피토프 제시 감소
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202016131A (zh) * 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
AU2019275072A1 (en) * 2018-05-23 2021-01-21 Seattle Project Corp. Shared antigens
CN110627895B (zh) * 2018-06-25 2021-03-23 北京大学 肺癌特异性tcr及其分析技术和应用
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
US20220143099A1 (en) * 2019-04-02 2022-05-12 The General Hospital Corporation Methods to enhance t cell regeneration
IL288283B2 (en) 2019-05-30 2025-05-01 Gritstone Bio Inc Modified adenovirus
WO2021016109A1 (en) * 2019-07-19 2021-01-28 The Regents Of The University Of California T-cell receptors and methods of use thereof
CN111020024A (zh) * 2019-12-05 2020-04-17 复旦大学附属眼耳鼻喉科医院 Tlr9的应用
CN111808908A (zh) * 2020-06-18 2020-10-23 华中科技大学同济医学院附属协和医院 一种促脑胶质瘤耐药的gaMSCs亚群的检测方法
EP4255465A4 (en) * 2020-12-07 2025-02-26 Iogenetics, LLC. Bystander protein vaccines
WO2022125339A2 (en) * 2020-12-07 2022-06-16 The Trustees Of Indiana University Methods to sensitize cancer cells to immune attack using atractylenolide i
CN113881707B (zh) * 2021-10-25 2023-07-14 中国人民解放军军事科学院军事医学研究院 调控脐带间充质干细胞免疫抑制作用的产品、方法及用途
CN113969264B (zh) * 2021-11-29 2023-12-08 中南大学 Cog5基因敲除的人胚胎干细胞系、构建方法及应用
CN115125203B (zh) * 2022-07-08 2023-10-27 珠海贝索细胞科学技术有限公司 一种Th2细胞体外培养方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212000B2 (en) * 1970-02-11 2012-07-03 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
BR7908410A (pt) 1978-12-22 1980-09-09 Biogen Nv Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
DE69405102T2 (de) 1993-06-03 1998-01-15 Therapeutic Antibodies, Inc., Nashville, Tenn. Antikoerperfragmente in therapie
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
WO1997026328A1 (en) 1996-01-17 1997-07-24 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
JP2004503213A (ja) 2000-03-27 2004-02-05 テクニオン　リサーチ　アンド　ディベロップメント　ファウンデーション　リミテッド １本鎖クラスｉ主要組織適合性複合体、それをコードする構築物およびそれを生成する方法
US20030144474A1 (en) 2000-06-05 2003-07-31 Sunol Molecular Corporation T cell receptor fusions and conjugates and methods of use thereof
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CA2457065A1 (en) * 2001-08-13 2003-02-27 Dana-Farber Cancer Institute, Inc. Periostin-based diagnostic assays
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20030223994A1 (en) 2002-02-20 2003-12-04 Hoogenboom Henricus Renerus Jacobus Mattheus MHC-peptide complex binding ligands
WO2004018633A2 (en) * 2002-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Abca13 nucleic acids and proteins, and uses thereof
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
EP2048159B1 (en) 2002-11-09 2014-01-01 Immunocore Ltd. T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
KR100535326B1 (ko) * 2004-01-20 2005-12-09 한국생명공학연구원 줄기 세포로부터 자연살해 세포로의 분화 조절용 유전자를유효성분으로 포함하는 분화 조절제
CN104072614B (zh) * 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
PT1760089E (pt) * 2005-09-05 2009-10-19 Immatics Biotechnologies Gmbh Peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antigénio leucocitário humano (hla) e correspondente vacina anti-cancerígena
ATE461214T1 (de) 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
AU2007218158A1 (en) * 2006-02-22 2007-08-30 Philogen Spa Vascular tumor markers
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
UA117216C2 (uk) * 2007-07-27 2018-07-10 Імматікс Біотекнолоджіс Гмбх Пухлиноасоційований пептид та його застосування
WO2009036246A2 (en) * 2007-09-14 2009-03-19 Immunotope, Inc. Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer
NZ585559A (en) * 2007-11-13 2012-11-30 Teva Biopharmaceuticals Usa Inc Humanized antibodies against tl1a
US7996174B2 (en) * 2007-12-18 2011-08-09 Teradyne, Inc. Disk drive testing
US8114968B2 (en) * 2008-03-03 2012-02-14 Dyax Corp. Metalloproteinase-12 specific monoclonal antibody
JP2011516077A (ja) * 2008-04-11 2011-05-26 チャイナ シンセティック ラバー コーポレイション 癌を検出するための方法、薬剤、およびキット
ATE462442T1 (de) 2008-04-30 2010-04-15 Immatics Biotechnologies Gmbh Neuartige formulierungen von tumor-assoziierten peptiden, welche an menschliche leukozytenantigene der klasse i oder ii für impfungen binden
TWI526219B (zh) * 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
EP2331577B1 (en) * 2008-08-29 2017-06-07 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
EP2172211B1 (en) * 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
WO2010045388A2 (en) * 2008-10-14 2010-04-22 Dyax Corp. Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
EP2221063A1 (en) * 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
AU2010248227B2 (en) * 2009-05-15 2016-02-25 Pacific Edge Limited Markers for detection of gastric cancer
US20110033516A1 (en) * 2009-08-06 2011-02-10 Medical University Of South Carolina Methods and compositions for bone healing by periostin
US8281198B2 (en) 2009-08-07 2012-10-02 Via Technologies, Inc. User-initiatable method for detecting re-grown fuses within a microprocessor
JP2013508409A (ja) * 2009-10-23 2013-03-07 トランザイム・ファーマ，インコーポレイテッド セリンプロテアーゼ酵素の大環状阻害剤
TWI485245B (zh) * 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
KR101378919B1 (ko) * 2010-01-28 2014-04-14 포항공과대학교 산학협력단 혈액으로부터 직접 폐암 진단 및 폐암의 서브타입 진단이 가능한 마커를 선별하는 시스템 생물학적 방법 및 이로부터 선별된 혈액으로부터 직접 폐암 진단 및 폐암 서브타입 진단이 가능한 마커
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) * 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
US20140170168A1 (en) 2010-10-26 2014-06-19 Yoram Reiter Antibodies which bind soluble t-cell receptor ligands
US9028810B2 (en) * 2010-12-20 2015-05-12 Ajou University Industry—Academic Cooperations Foundatin Composition for inducing migration of neural stem cells containing periostin as effective ingredient
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors

Also Published As

Publication number Publication date
TW202041516A (zh) 2020-11-16
TW201506043A (zh) 2015-02-16
KR102211542B1 (ko) 2021-02-02
NZ733168A (en) 2020-04-24
KR102098327B1 (ko) 2020-04-08
KR20200078681A (ko) 2020-07-01
ES2764406T3 (es) 2020-06-03
KR20200122418A (ko) 2020-10-27
AU2018200389B2 (en) 2020-07-16
CA3073256A1 (en) 2015-02-12
TWI714869B (zh) 2021-01-01
AU2020220038A1 (en) 2020-09-03
AU2020220043B2 (en) 2021-11-25
EP3616711B1 (en) 2025-01-15
SI3030255T1 (sl) 2020-02-28
KR20180105754A (ko) 2018-09-28
AU2020220041A1 (en) 2020-09-03
DK3456339T3 (da) 2021-12-06
MX389568B (es) 2025-03-20
SG10202002612PA (en) 2020-05-28
JP2016527293A (ja) 2016-09-08
KR20200123266A (ko) 2020-10-28
MX2016001426A (es) 2016-05-05
CA2912500A1 (en) 2015-02-12
AU2020220044B2 (en) 2021-11-25
KR20160038889A (ko) 2016-04-07
AU2020220044A1 (en) 2020-09-03
AU2020220040B2 (en) 2021-11-25
KR102317816B1 (ko) 2021-10-26
SG10202002608WA (en) 2020-04-29
US20160168200A1 (en) 2016-06-16
EP3613427B1 (en) 2025-01-15
AU2020220039A1 (en) 2020-09-03
TW202041518A (zh) 2020-11-16
EP3578196A1 (en) 2019-12-11
AU2020220045A1 (en) 2020-09-03
TWI777197B (zh) 2022-09-11
US20170202937A1 (en) 2017-07-20
RS59861B1 (sr) 2020-03-31
EA035362B1 (ru) 2020-06-02
EP3613427A1 (en) 2020-02-26
EP3456339B1 (en) 2021-10-20
KR102217680B1 (ko) 2021-02-18
PE20160717A1 (es) 2016-07-21
TWI777194B (zh) 2022-09-11
TW202041515A (zh) 2020-11-16
KR20200122419A (ko) 2020-10-27
US10071148B2 (en) 2018-09-11
EP3616710A1 (en) 2020-03-04
CR20210464A (es) 2021-10-26
US20170319675A1 (en) 2017-11-09
IL243788B (en) 2019-10-31
KR102213552B1 (ko) 2021-02-05
TW202041522A (zh) 2020-11-16
AU2020220045B2 (en) 2021-11-25
EP3616707A1 (en) 2020-03-04
EP3456339A2 (en) 2019-03-20
EP3616710B1 (en) 2025-01-15
EP3030255B1 (en) 2019-10-09
SG11201510580UA (en) 2016-02-26
TW202041520A (zh) 2020-11-16
DK3030255T3 (da) 2020-01-20
TW202041521A (zh) 2020-11-16
EP3616708A1 (en) 2020-03-04
EP3616708B1 (en) 2025-01-08
CR20200139A (es) 2020-09-02
TW202041517A (zh) 2020-11-16
HUE047079T2 (hu) 2020-04-28
HK1222121A1 (zh) 2017-06-23
EP3030255A1 (en) 2016-06-15
KR102213556B1 (ko) 2021-02-05
AU2014304544A1 (en) 2015-12-03
CA3020939A1 (en) 2015-02-12
TWI776192B (zh) 2022-09-01
LT3030255T (lt) 2020-01-27
EA201690016A1 (ru) 2016-05-31
AU2018200389A1 (en) 2018-02-08
AU2020220039B2 (en) 2021-05-20
KR20180107295A (ko) 2018-10-01
CN105377290B (zh) 2019-09-03
CN105377290A (zh) 2016-03-02
CA3073394A1 (en) 2015-02-12
TWI777198B (zh) 2022-09-11
CA2912500C (en) 2021-08-24
CL2016000227A1 (es) 2016-08-05
KR102098329B1 (ko) 2020-04-09
AU2014304544B2 (en) 2017-10-26
KR20200122417A (ko) 2020-10-27
CA3020939C (en) 2023-01-03
EP3616709A1 (en) 2020-03-04
AU2020220041B2 (en) 2021-11-25
US9943579B2 (en) 2018-04-17
AU2020220038B2 (en) 2021-11-25
EP3616711A1 (en) 2020-03-04
KR102213551B1 (ko) 2021-02-05
TWI777195B (zh) 2022-09-11
WO2015018805A1 (en) 2015-02-12
TW201900669A (zh) 2019-01-01
PH12015502638A1 (en) 2016-03-07
BR112016000810A2 (pt) 2017-12-12
AU2020220042A1 (en) 2020-09-03
KR20210008169A (ko) 2021-01-20
PL3030255T3 (pl) 2020-05-18
TW202041519A (zh) 2020-11-16
UA122661C2 (uk) 2020-12-28
TWI819228B (zh) 2023-10-21
SG10201802399WA (en) 2018-04-27
EP3616712A1 (en) 2020-03-04
KR102213554B1 (ko) 2021-02-05
AU2020220043A1 (en) 2020-09-03
TWI777196B (zh) 2022-09-11
TWI775117B (zh) 2022-08-21
EP3616709B1 (en) 2025-01-15
PT3030255T (pt) 2020-01-15
TWI636065B (zh) 2018-09-21
EP3456339A3 (en) 2019-03-27
AU2020220042B2 (en) 2021-11-25
NZ714163A (en) 2017-07-28
PE20181538A1 (es) 2018-09-26
CR20160018A (es) 2016-06-08
CR20180508A (es) 2019-02-27
AU2020220040A1 (en) 2020-09-03
IL243788A0 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
PE20201284A1 (es) Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc)
MX2016005866A (es) Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
CR20160531A (es) Inmunoterapia novedosa contra varios tumores de la sangre, como la leucemia mielógena aguda (lma)
MX2019011621A (es) Inmunoterapia novedosa contra varios tumores, tales como cancer de pulmon, que incluye cancer de pulmon de celula no pequeña (nsclc).
MX355074B (es) Inmunoterapia novedosa contra varios tumores incluidos el cancer gastrico y gastrointestinal.
MX2019013163A (es) Inmunoterapia novedosa contra varios tumores de la sangre, con la leucemia mielogena aguda (lma).
AR118181A2 (es) Inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc)
AR113131A2 (es) Inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc)
MX2019013161A (es) Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
EA202090822A2 (ru) Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл
AR100926A1 (es) Inmunoterapia contra varios tumores de la sangre, en particular contra la leucemia linfoide crónica (llc)
EA201990696A1 (ru) Персонализированная иммунотерапия нескольких видов нейрональных опухолей и опухолей головного мозга
MY194653A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MY194244A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc
MY194241A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC
MY193910A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc